Answers are grounded in this paper and cite their sources.
There is direct evidence supporting the use of SGLT2 inhibitors in reducing the risk of nephrolithiasis, including calcium-based stones, primarily driven by their physiological effects on urine composition and flow.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: